Supriya Lifescience Ltd
NSE:SUPRIYA
Supriya Lifescience Ltd
Supriya Lifescience Ltd. supplies active pharmaceuticals ingredients (“APIs”), with a focus on research and development. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2021-12-28. The company focuses on products in various therapeutic segments, such as Anti-Histamine, Anti-Allergics, Vitamins, Anesthetics and Anti-Asthmatics. Its manufacturing facilities include delineated areas for quality check (QC); manufacturing areas with multiple clean rooms; engineering and maintenance; warehouse; materials and finished goods stores; in-house microbiological laboratory, and functional waste treatment plant. The company handles chemical reactions, such as Friedel Craft’s Acylation, Claisen Condensation, Grignard Reaction, Mannich Reaction, Ritter Reaction, Eschweiler Clark reaction, Hydrogenation, Chlorination, Bromination, Decyanation, Isocyanation, Ethoxylation, Nitration, Alkylation, Reduction, Oxidation, Etherification, Chlorosulphonation, Phosphorylation, Chiral resolution, Heterocyclic chemistry, Thermal ring expansion and Protection/Deprotection.
Supriya Lifescience Ltd. supplies active pharmaceuticals ingredients (“APIs”), with a focus on research and development. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2021-12-28. The company focuses on products in various therapeutic segments, such as Anti-Histamine, Anti-Allergics, Vitamins, Anesthetics and Anti-Asthmatics. Its manufacturing facilities include delineated areas for quality check (QC); manufacturing areas with multiple clean rooms; engineering and maintenance; warehouse; materials and finished goods stores; in-house microbiological laboratory, and functional waste treatment plant. The company handles chemical reactions, such as Friedel Craft’s Acylation, Claisen Condensation, Grignard Reaction, Mannich Reaction, Ritter Reaction, Eschweiler Clark reaction, Hydrogenation, Chlorination, Bromination, Decyanation, Isocyanation, Ethoxylation, Nitration, Alkylation, Reduction, Oxidation, Etherification, Chlorosulphonation, Phosphorylation, Chiral resolution, Heterocyclic chemistry, Thermal ring expansion and Protection/Deprotection.
Revenue Growth: Q3 FY '26 revenue grew 11% year-on-year to INR 206 crores, with strong export demand driving performance.
Margins: EBITDA margin was stable at 35%, and PAT margin was 24.1%, in line with management's historical guidance.
Exports: Exports made up 82% of revenue, with LatAm and North America showing healthy growth.
Guidance Maintained: Management reaffirmed guidance of 20% annual revenue growth and EBITDA margin of 33%-35% for FY '26, despite Q3 sales impact from holiday shipment delays.
Product Pipeline: Several new products launched, including a key cardiovascular drug and ADHD product; Ambernath facility set for commercialization in Q4 with revenue contribution expected in FY '27.
CapEx: CapEx for 9 months stood at INR 71 crores, mainly for the Ambernath facility, with total Ambernath spending expected at INR 140–160 crores.
Order Visibility: Management expressed strong confidence in Q4 revenue due to a robust order book and spillover from Q3.
